Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases

References

• Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev. 2003;2:181–91.
   PubMed Web of Science ®Google Scholar
• Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000;12:527–33.
   PubMed Web of Science ®Google Scholar
• LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin N Am. 1996;22:675–94.
   PubMed Web of Science ®Google Scholar
• Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheuma-tology (Oxford). 2010;49(12):2375–80.
   PubMedGoogle Scholar
• Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endo-thelial dysfunction in children and adults at risk of atheroscle-rosis. Lancet. 1992;340:1111–5.
   PubMed Web of Science ®Google Scholar
• Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circula-tion. 1995;91:1314–9.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56:1985–93.
   PubMedGoogle Scholar
• Mihai C, Tervaert JW. Anti-endothelial cell antibodies in sys-temic sclerosis. Ann Rheum Dis. 2010;69:319–24.
   PubMed Web of Science ®Google Scholar
• Worda M, Sgonc R, Dietrich H, Niederegger H, Sundick RS, Gershwin ME, et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum. 2003;48:2605–14.
   PubMedGoogle Scholar
• Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998;101:2029–35.
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43:2550–62.
   PubMed Web of Science ®Google Scholar
• Wusirika R, Ferri C, Mann M, Knight DA, Waldman WJ, Ross P Jr, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol. 2003;120: 596–606.
   Google Scholar
• Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y, et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the patho-physiology of systemic sclerosis. J Immunol. 2005;174:5740–9.
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785–92.
   PubMed Web of Science ®Google Scholar
• Pana ER, Aguiar AC Jr, Teodoro WR, de Souza R, Yoshinari NH, Capelozzi VL. Collagen V and vascular injury promote lung architectural changes in systemic sclerosis. Clin Respir J. 2009;3:135–42.
   PubMedGoogle Scholar
• Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev. 2011;10:248–55.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940–4.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treat-ment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Berezne A, Guillevin L, Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med. 2010;104(Suppl 1):559–69.
   Google Scholar
• Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:679–85.
   Google Scholar
• Casale R, Generini S, Luppi F, Pignone A, Matucci-Cerinic M. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dys-function (Raynaud's phenomenon) in a case of early systemic sclerosis. Arthritis Rheum. 2004;51:665–9.
   Google Scholar
• Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Hazned-aroglu IC, et al. Effects of oral cyclophosphamide and prednis-olone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum. 2003;48:2256–61.
   Google Scholar
• Caramaschi P, Volpe A, Pieropan S, Tinazzi I, Mahamid H, Bambara LM, et al. Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin Rheumatol. 2009;28:391–5.
   PubMed Web of Science ®Google Scholar
• Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzomi C, et al. Brachial artery endothelial-dependent flow-mediated dila-tion identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol. 2010;37:1168–73.
   PubMed Web of Science ®Google Scholar